Zydus Lifesciences forms JV with Sunshine Healthcare Lanka for Sri Lanka manufacturing
Zydus Lifesciences has formed a 50:50 joint venture with Sunshine Healthcare Lanka to establish Zydus Sunshine Lifesciences (Private) Limited, a pharmaceutical manufacturing entity in Sri Lanka. The company will invest up to USD 5 million to subscribe to 50% of the equity, with a total project commitment of over USD 20 million. The facility, located in the Horana Export Processing Zone, aims to reduce import dependence and improve access to high-quality medicines.

*this image is generated using AI for illustrative purposes only.
Zydus Lifesciences has entered into a joint venture with Sunshine Healthcare Lanka Limited to establish a pharmaceutical manufacturing facility in Sri Lanka, aiming to strengthen local production and reduce import dependence. The joint venture entity, Zydus Sunshine Lifesciences (Private) Limited, will see both partners hold equal stakes, with Zydus subscribing to 50% of the total paid-up equity share capital. The project involves an investment commitment of over USD 20 million to develop a state-of-the-art facility in the Board of Investment zone in Horana.
The Share Subscription and Shareholders’ Agreement was signed on June 26, 2026. Zydus Lifesciences will subscribe to the shares through a cash consideration of up to USD 5 million in one or more tranches, subject to specific adjustments. The subscription is expected to be completed within 90 working days from the date of execution of the agreement. The target entity, incorporated on May 30, 2026, currently has nil turnover as it is a recently established company.
Joint Venture Structure and Governance
The Board of Zydus Sunshine Lifesciences will comprise six directors, with three representatives each from Zydus Lifesciences and Sunshine Healthcare Lanka. Zydus will appoint the Chairperson, who will hold a casting vote on all matters except reserved matters. Any changes to the capital structure will require the approval of both partners. The transaction does not fall within related party transactions, and none of the promoter or group companies have any interest in the subscription.
The facility will be developed on nearly four acres of land in the Horana Export Processing Zone. It will focus on manufacturing pharmaceutical products for Sri Lanka's retail market. The project is designed to support national supply chain resilience and enhance the availability of essential medicines under the oversight of the Board of Investment of Sri Lanka, with the Ministry of Health and the National Medicines Regulatory Authority as key stakeholders.
| Particulars | Details |
|---|---|
| Name of Target Entity | Zydus Sunshine Lifesciences (Private) Limited |
| Date of Incorporation | May 30, 2026 |
| Shareholding Acquired | 50% |
| Cost of Acquisition | Up to USD 5 million |
| Total Investment Commitment | Over USD 20 million |
| Location | Horana Export Processing Zone, Sri Lanka |
| Industry | Pharmaceuticals |
Historical Stock Returns for Zydus Life Science
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.26% | +0.51% | +6.05% | +32.92% | +19.25% | +80.24% |
What is the projected timeline for the facility to become fully operational and begin commercial production?
Which specific therapeutic segments or essential medicines will be prioritized for manufacturing at the new facility?
How will this joint venture impact Zydus Lifesciences' revenue contribution from international markets over the next fiscal year?































